Johnson & Johnson (JNJ) announced last night its decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

This report covers significant developments in the health sector, including Johnson & Johnson halting a depression drug trial ...

Johnson & Johnson (NYSE:JNJ) has decided to discontinue a Phase 3 program for its depression therapy aticaprant due to insufficient efficacy, the pharma giant announced. Known as VENTURA ...

Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an ...

J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.